Exicure, Inc. Receives Extension From Nasdaq Hearings Panel
Exicure, Inc. Receives Extension From Nasdaq Hearings Panel
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see .CHICAGO--(BUSINESS WIRE)--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel ("Panel") granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel's requests and to ensure the Company's continued listing on Nasdaq.
Exicure, Inc.（"Exicure"或「公司」）（納斯達克：XCUR）於2024年9月17日獲悉，納斯達克聽證委員會（"委員會"）同意延長公司繼續上市的期限，前提是公司在2024年11月14日之前證明符合納斯達克資本市場的持續上市的所有適用標準。公司正在努力及時滿足委員會的要求，並確保公司能繼續在納斯達克上市。
As previously announced, the Company has regained compliance with Nasdaq's minimum bid price requirement and exchanged approximately $1,000,000 of indebtedness for equity at a conversion price of $3.00 per share.
如先前公告的，公司已恢復了納斯達克的最低買盤價格要求，並以3.00美元每股的轉換價值，將約100萬美元的債務轉換爲股權。
About Exicure
關於Exicure
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see .
Exicure，Inc.歷來是一家專注於開發核苷酸治療方案的早期生物技術公司，針對已驗證的靶點進行RNA靶向。在最近的重組和臨床開發活動暫停之後，該公司正在探索戰略性的選擇，以最大化股東價值，包括其歷史悠久的生物技術資產以及更廣泛的資產。欲了解更多信息，請參見。
譯文內容由第三人軟體翻譯。